Seelos Therapeutics Inc (SEEL) gains 5.35% for July 21

Equities Staff  |

Seelos Therapeutics Inc (NASDAQ: SEEL) shares gained 5.35%, or $0.13 per share, to close Wednesday at $2.56. After opening the day at $2.44, shares of Seelos fluctuated between $2.57 and $2.40. 2,390,708 shares traded hands a decrease from their 30 day average of 4,103,680. Wednesday's activity brought Seelos’s market cap to $201,172,534.

Seelos is headquartered in New York, New York..

About Seelos Therapeutics Inc

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

Visit Seelos Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Seelos Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Seelos Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content